A company insider recently sold 1,912 shares of Roivant Sciences Ltd. [ROIV]. Should You Sale?


Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Roivant Sciences Ltd. shares valued at $15,449 were sold by Pulik Richard on Mar 01. At $8.08 per share, Pulik Richard sold 1,912 shares. The insider’s holdings dropped to 223,347 shares worth approximately $1.9 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, Ramaswamy Vivek sold 4,000,000 shares, netting a total of over 31,800,000 in proceeds. Following the sale of shares at $7.95 each, the insider now holds 54,409,211 shares.

Before that, Venker Eric had sold 24,037 shares from its account. In a trade valued at $192,777, the President & COO traded Roivant Sciences Ltd. shares for $8.02 each. Upon closing the transaction, the insider’s holdings decreased to 24,037 shares, worth approximately $6.2 million.

As published in their initiating research note from JP Morgan on October 27, 2022, Roivant Sciences Ltd. [ROIV] has been an Overweight and the price target has been revised to $7. This represents a -21.43% premium over Thursday’s closing price. Analysts at SVB Leerink started covering the stock with ‘”an Outperform”‘ outlook in a report released in late May. As of April 29, 2022, Cantor Fitzgerald has initiated its “an Overweight” rating for ROIV. Earlier on December 15, 2021, Goldman initiated its rating. Their recommendation was “a Buy” for ROIV stock.

Analyzing ROIV Stock Performance

On Thursday, Roivant Sciences Ltd. [NASDAQ: ROIV] plunged -1.05% to $8.50. The stock’s lowest price that day was $8.33, but it reached a high of $8.60 in the same session. During the last five days, there has been a surge of approximately 10.53%. Over the course of the year, Roivant Sciences Ltd. shares have jumped approximately 6.38%. Shares of the company reached a 52-week high of $10.00 on 01/12/23 and a 52-week low of $6.65 on 01/04/23. A 50-day SMA is recorded $8.40, while a 200-day SMA reached $5.59. Nevertheless, trading volume fell to 2.04 million shares from 1.68 million shares the previous day.

Support And Resistance Levels for Roivant Sciences Ltd. (ROIV)

According to the 24-hour chart, there is a support level at 8.35, which, if violated, would cause prices to drop to 8.21. In the upper region, resistance lies at 8.62. The next price resistance is at 8.75. RSI (Relative Strength Index) is 56.26 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.30, which suggests the price will decrease in the coming days. Percent R is at 30.38%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Roivant Sciences Ltd. subject to short interest?

Stocks of Roivant Sciences Ltd. saw a sharp steep in short interest on Jan 30, 2023 dropping by -3.57 million shares to 12.83 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 16.4 million shares. A decline of -27.83% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.85 of the overall float, the days-to-cover ratio (short ratio) decline to 4.85.

Which companies own the most shares of Roivant Sciences Ltd. (ROIV)?

According to QVT Financial LP filings, the company currently owns 122,541,536 shares, which is about 16.16% of the total ROIV shares outstanding. The investor’s shares have plunged by -6,852,281 from its previous 13-F filing of 129393817.0 shares. Fidelity Management & Research Co acquire a 627.46% interest valued at $245.71 million while Adage Capital Management LP purchased a 5,298,439 stake. A total of 540,750 shares of Roivant Sciences Ltd. were bought by Two Seas Capital LP during the quarter, and 57,694 were bought by BlackRock Fund Advisors. In its current portfolio, Anchorage Capital Group LLC holds 4,832,642 shares valued at $39.1 million.

On November 08, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $14.


Please enter your comment!
Please enter your name here